Kelly Jared 4

What Happened

• Kelly Jared, CEO of Oncolytics Biotech Inc. (ONCY), received a grant of 755,000 derivative securities on June 1, 2026. The filing reports an acquisition amount of $0 because this is an option/award (transaction code A).
• The exercise/strike price is equal to the closing price of ONCY common stock on the Nasdaq on June 1, 2026 (see footnote F1). There is no immediate intrinsic value reported because the grant is at-the-money.

Key Details

• Transaction date: 2026-06-01; Form 4 filed: 2026-06-03.
• Instrument: Stock option/award (derivative); 755,000 units granted; reported acquisition price $0.00.
• Exercise/strike price: equal to Nasdaq closing price on 2026-06-01 (footnote F1).
• Vesting: Options vest in three equal annual installments; first vesting on 2027-06-01, subject to continued service (footnote F2).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filing was submitted two days after the grant; no late-filing flag is indicated.

Context

• This was an award of options, not an open-market purchase or sale. Options granted at the closing price are typically at-the-money and require future vesting and exercise (and payment of the strike) before becoming owned shares.
• Such grants are common executive compensation/retention mechanisms and do not by themselves indicate immediate buying or selling of stock.